title: TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
authors.affiliation: Unit of Dermatology, University of Padua, Via C. Battisti 206, 35128 Padova, Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Zattra
authors.forename: Roxana
authors.initials: R
authors.lastname: Stan
authors.forename: Irene
authors.initials: I
authors.lastname: Russo
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lo Nigro
authors.forename: Andrea
authors.initials: A
authors.lastname: Peserico
authors.forename: Mauro
authors.initials: M
authors.lastname: Alaibac
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D064420:Drug-Related Side Effects and Adverse Reactions / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007372:Interferons / Q000037:antagonists & inhibitors; D000077269:Lenalidomide; D008178:Lupus Erythematosus, Cutaneous / Q000276:immunology / Q000628:therapy*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D019138:Antibodies, Blocking; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D007372:Interferons; D000077269:Lenalidomide